Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis with Telbivudine or Adefovir

2007191 citationsJournal Article

Authors

Henry Lik‐Yuen Chan · Hôpital Beaujon

E. Jenny Heathcote · Victoria General Hospital

Patrick Marcellin · Victoria General Hospital

Ching-Lung Lai · Victoria General Hospital

Mong Cho · Chinese University of Hong Kong

Young M. Moon · Victoria General Hospital

You-Chen Chao · Victoria General Hospital

Robert P. Myers

Abstract

Telbivudine demonstrated greater and more consistent HBV DNA suppression than adefovir after 24 weeks of treatment. After 52 weeks, HBV DNA suppression was greater in patients who had received continuous telbivudine or were switched to telbivudine after 24 weeks than in those who received continuous adefovir.

Topics & Keywords

Hepatitis B Virus Studies Hepatitis C virus research Hepatitis Viruses Studies and Epidemiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Internal Medicine

Volume 147, Issue 11, pp. 745-754

DOI: 10.7326/0003-4819-147-11-200712040-00183

Field-Weighted Citation Impact: 19.89